Other Species / Isoforms
  ARPP-19 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsAEVPEAA
0 6
ARPP-19 (human) ______MsAEVPEAA S2-p
ARPP-19 iso2 (human) gap -
ARPP-19 (mouse) ______MsAEVPEAA S2-p
ARPP-19 (rat) ______MsAEVPEAA S2-p
S10-p
AEVPEAAsAEEQKEM
0 4
ARPP-19 (human) AEVPEAAsAEEQKEM S10-p
ARPP-19 iso2 (human) gap -
ARPP-19 (mouse) AEVPEAAsAEEQKEM S10-p
ARPP-19 (rat) AEVPEAASAEEQKEM S10
K20
EQKEMEDKVtsPEkA
0 1
ARPP-19 (human) EQKEMEDKVtsPEkA K20
ARPP-19 iso2 (human) ____MEDKVTSPEKA K4
ARPP-19 (mouse) EQKEMEDKVtsPEKA K20
ARPP-19 (rat) EQKEMEDkVTSPEKA K20-ac
T22-p
KEMEDKVtsPEkAEE
0 2
ARPP-19 (human) KEMEDKVtsPEkAEE T22-p
ARPP-19 iso2 (human) __MEDKVTSPEKAEE T6
ARPP-19 (mouse) KEMEDKVtsPEKAEE T22-p
ARPP-19 (rat) KEMEDkVTSPEKAEE T22
S23-p
EMEDKVtsPEkAEEA
0 17
ARPP-19 (human) EMEDKVtsPEkAEEA S23-p
ARPP-19 iso2 (human) _MEDKVTSPEKAEEA S7
ARPP-19 (mouse) EMEDKVtsPEKAEEA S23-p
ARPP-19 (rat) EMEDkVTSPEKAEEA S23
K26-ac
DKVtsPEkAEEAkLk
0 4
ARPP-19 (human) DKVtsPEkAEEAkLk K26-ac
ARPP-19 iso2 (human) DKVTSPEKAEEAKLK K10
ARPP-19 (mouse) DKVtsPEKAEEAKLK K26
ARPP-19 (rat) DkVTSPEKAEEAkLK K26
K31-ac
PEkAEEAkLkAryPH
0 4
ARPP-19 (human) PEkAEEAkLkAryPH K31-ac
ARPP-19 iso2 (human) PEKAEEAKLKARYPH K15
ARPP-19 (mouse) PEKAEEAKLKARyPH K31
ARPP-19 (rat) PEKAEEAkLKARYPH K31-ac
K33-ac
kAEEAkLkAryPHLG
0 1
ARPP-19 (human) kAEEAkLkAryPHLG K33-ac
ARPP-19 iso2 (human) KAEEAKLKARYPHLG K17
ARPP-19 (mouse) KAEEAKLKARyPHLG K33
ARPP-19 (rat) KAEEAkLKARYPHLG K33
R35-m1
EEAkLkAryPHLGQk
0 1
ARPP-19 (human) EEAkLkAryPHLGQk R35-m1
ARPP-19 iso2 (human) EEAKLKARYPHLGQK R19
ARPP-19 (mouse) EEAKLKARyPHLGQK R35
ARPP-19 (rat) EEAkLKARYPHLGQk R35
Y36-p
EAkLkAryPHLGQkP
0 25
ARPP-19 (human) EAkLkAryPHLGQkP Y36-p
ARPP-19 iso2 (human) EAKLKARYPHLGQKP Y20
ARPP-19 (mouse) EAKLKARyPHLGQKP Y36-p
ARPP-19 (rat) EAkLKARYPHLGQkP Y36
K42-ac
ryPHLGQkPGGsDFL
0 4
ARPP-19 (human) ryPHLGQkPGGsDFL K42-ac
ARPP-19 iso2 (human) RYPHLGQKPGGSDFL K26
ARPP-19 (mouse) RyPHLGQKPGGSDFL K42
ARPP-19 (rat) RYPHLGQkPGGSDFL K42-ac
K42-ub
ryPHLGQkPGGsDFL
0 2
ARPP-19 (human) ryPHLGQkPGGsDFL K42-ub
ARPP-19 iso2 (human) RYPHLGQKPGGSDFL K26
ARPP-19 (mouse) RyPHLGQKPGGSDFL K42
ARPP-19 (rat) RYPHLGQKPGGSDFL K42
S46-p
LGQkPGGsDFLRKRL
0 2
ARPP-19 (human) LGQkPGGsDFLRKRL S46-p
ARPP-19 iso2 (human) LGQKPGGSDFLRKRL S30
ARPP-19 (mouse) LGQKPGGSDFLRKRL S46
ARPP-19 (rat) LGQkPGGSDFLRKRL S46
K58-ac
KRLQKGQkyFDsGDy
0 20
ARPP-19 (human) KRLQKGQkyFDsGDy K58-ac
ARPP-19 iso2 (human) KRLQKGQKYFDsGDY K42
ARPP-19 (mouse) KRLQKGQkyFDsGDy K58-ac
ARPP-19 (rat) KRLQKGQkyFDsGDy K58-ac
K58-ub
KRLQKGQkyFDsGDy
0 6
ARPP-19 (human) KRLQKGQkyFDsGDy K58-ub
ARPP-19 iso2 (human) KRLQKGQKYFDsGDY K42
ARPP-19 (mouse) KRLQKGQkyFDsGDy K58-ub
ARPP-19 (rat) KRLQKGQKyFDsGDy K58
Y59-p
RLQKGQkyFDsGDyN
Upstream
0 343
Treatment
  • erlotinib
ARPP-19 (human) RLQKGQkyFDsGDyN Y59-p
ARPP-19 iso2 (human) RLQKGQKYFDsGDYN Y43
ARPP-19 (mouse) RLQKGQkyFDsGDyN Y59-p
ARPP-19 (rat) RLQKGQkyFDsGDyN Y59-p
S62-p
KGQkyFDsGDyNMAk
Upstream
1 112
ARPP-19 (human)
S62-p
ARPP-19 (mouse)
S62-p
ARPP-19 (rat)
S62-p
Treatment
  • angiotensin-(1-7)
  • anti-CD3
  • metastatic potential
ARPP-19 (human) KGQkyFDsGDyNMAk S62-p
ARPP-19 iso2 (human) KGQKYFDsGDYNMAK S46-p
ARPP-19 (mouse) KGQkyFDsGDyNMAK S62-p
ARPP-19 (rat) KGQkyFDsGDyNMAK S62-p
Y65-p
kyFDsGDyNMAkAkM
Upstream
1 552
Treatment
  • ephrin_B1
  • ephrin_B2
  • erlotinib
  • FGF2
  • gefitinib
  • Su11274
  • U0126
ARPP-19 (human) kyFDsGDyNMAkAkM Y65-p
ARPP-19 iso2 (human) KYFDsGDYNMAKAKM Y49
ARPP-19 (mouse) kyFDsGDyNMAKAKM Y65-p
ARPP-19 (rat) kyFDsGDyNMAKAKM Y65-p
K69-ub
sGDyNMAkAkMKNKQ
0 6
ARPP-19 (human) sGDyNMAkAkMKNKQ K69-ub
ARPP-19 iso2 (human) sGDYNMAKAKMKNKQ K53
ARPP-19 (mouse) sGDyNMAKAKMKNKQ K69
ARPP-19 (rat) sGDyNMAKAKMKNKQ K69
K71-ub
DyNMAkAkMKNKQLP
0 1
ARPP-19 (human) DyNMAkAkMKNKQLP K71-ub
ARPP-19 iso2 (human) DYNMAKAKMKNKQLP K55
ARPP-19 (mouse) DyNMAKAKMKNKQLP K71
ARPP-19 (rat) DyNMAKAKMKNKQLP K71
T79-p
MKNKQLPtAAPDkTE
0 1
ARPP-19 (human) MKNKQLPtAAPDkTE T79-p
ARPP-19 iso2 (human) MKNKQLPTAAPDKTE T63
ARPP-19 (mouse) MKNKQLPAAAPDKTE A79
ARPP-19 (rat) MKNKQLPAAAPDkTE A79
K84-ac
LPtAAPDkTEVTGDH
0 2
ARPP-19 (human) LPtAAPDkTEVTGDH K84-ac
ARPP-19 iso2 (human) LPTAAPDKTEVTGDH K68
ARPP-19 (mouse) LPAAAPDKTEVTGDH K84
ARPP-19 (rat) LPAAAPDkTEVTGDH K84-ac
T94-p
VTGDHIPtPQDLPQR
0 5
ARPP-19 (human) VTGDHIPtPQDLPQR T94-p
ARPP-19 iso2 (human) VTGDHIPTPQDLPQR T78
ARPP-19 (mouse) VTGDHIPTPQDLPQR T94
ARPP-19 (rat) VTGDHIPTPQDLPQR T94
K102-ub
PQDLPQRkPsLVAsk
0 1
ARPP-19 (human) PQDLPQRkPsLVAsk K102-ub
ARPP-19 iso2 (human) PQDLPQRKPSLVASK K86
ARPP-19 (mouse) PQDLPQRKPsLVAsK K102
ARPP-19 (rat) PQDLPQRKPsLVASk K102
S104-p
DLPQRkPsLVAskLA
Upstream
1 116
Treatment
  • ischemia
ARPP-19 (human) DLPQRkPsLVAskLA S104-p
ARPP-19 iso2 (human) DLPQRKPSLVASKLA S88
ARPP-19 (mouse) DLPQRKPsLVAsKLA S104-p
ARPP-19 (rat) DLPQRKPsLVASkLA S104-p
S108-p
RkPsLVAskLAG___
0 7
ARPP-19 (human) RkPsLVAskLAG___ S108-p
ARPP-19 iso2 (human) RKPSLVASKLAG___ S92
ARPP-19 (mouse) RKPsLVAsKLAG___ S108-p
ARPP-19 (rat) RKPsLVASkLAG___ S108
K109-ac
kPsLVAskLAG____
0 9
ARPP-19 (human) kPsLVAskLAG____ K109-ac
ARPP-19 iso2 (human) KPSLVASKLAG____ K93
ARPP-19 (mouse) KPsLVAsKLAG____ K109
ARPP-19 (rat) KPsLVASkLAG____ K109-ac